No Data
No Data
Gilead Sciences | 10-Q: Quarterly report
S&P 500 Tries Its Best to Rebound With Best Day In A Year | Wall Street Today
Gilead Sciences Posts Higher 2Q Profit, Revenue on Increased Sales
Express News | Gilead Sciences Raises FY24 Adj EPS Forecast From $3.45 - $3.85 To $3.60 - $3.90, Est $3.75; Product Sales Outlook Unchanged
Gilead Sciences in Charts: Sales From HIV, Liver Disease, and Oncology Therapies Advances in Q2
Express News | Gilead Sciences Inc Shares up 0.54% at $76.00 in Extended Trade Following Results, Outlook
No Data
104247826 :